Last updated 6 months ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.
When COVID-19 vaccines rolled out across America in December 2020, most people didn’t realize they were receiving products that hadn’t received full FDA approval.
These vaccines were authorized through a special regulatory pathway called Emergency Use Authorization that allows the FDA to fast-track medical products during public health crises.
Emergency Use Authorization, or EUA, represents a powerful tool in the federal government’s public health arsenal. It allows the FDA to authorize relatively unproven drugs, vaccines, or medical devices during declared emergencies, bypassing the standard multi-year approval process that can take a decade or more.
While EUAs gained household recognition during the pandemic, the authority was actually created in response to the September 11 attacks and subsequent anthrax mailings in 2001. The mechanism was designed to strengthen America’s defenses against chemical, biological, radiological, and nuclear threats – not just naturally occurring diseases.
The EUA process embodies a fundamental tension in medical regulation: the need for speed versus the demand for certainty. It allows the FDA to balance the risk of deploying an unproven treatment against the risk of allowing a public health threat to go unchecked.
What Emergency Use Authorization Is
Medical Countermeasures in Crisis
An Emergency Use Authorization allows the FDA to make medical countermeasures available during public health emergencies. These countermeasures include vaccines, drugs, diagnostic tests, and medical devices used to diagnose, treat, or prevent serious or life-threatening diseases.
The authority grants the FDA significant flexibility during emergencies. An EUA can permit changes to a product’s official labeling or waive certain standard requirements, such as the need for informed consent from patients in clinical settings. This allows public health officials to deploy the best available tools to protect the public, even if those tools aren’t fully approved or are being used in new ways.
Legal Foundation
The FDA’s general authority to regulate medical products comes from the Federal Food, Drug, and Cosmetic Act of 1938. This landmark law emerged from the 1937 elixir sulfanilamide tragedy, where a manufacturer used a toxic solvent to create liquid antibiotic, killing more than 100 people, many of them children.
The specific authority to issue EUAs, however, came much later. Section 564 of the FD&C Act, added in 2004, provides the explicit legal framework for emergency authorization of medical products.
Historical Origins: From 9/11 to BioShield
Early Lessons in Medical Urgency
The concept of expediting medical product access evolved through decades of public health crises that highlighted the tension between caution and urgency.
The thalidomide tragedy of the 1950s and 1960s profoundly shaped the FDA’s safety-first culture. This drug for morning sickness caused severe birth defects in thousands of children outside the U.S., leading directly to the 1962 Kefauver-Harris Amendment requiring manufacturers to prove both safety and effectiveness.
Later crises created intense demand for faster access to unproven treatments. The 1976 swine flu scare prompted a national vaccination program under President Gerald Ford, though the feared pandemic never materialized. During the AIDS epidemic of the 1980s, patient advocates and public health experts pushed for new ways to get investigational drugs to dying patients, leading to “parallel track” systems – early precursors to modern expedited access pathways.
The 9/11 Catalyst
The September 11, 2001 terrorist attacks and subsequent anthrax mailings fundamentally reframed public health emergencies as national security threats. Letters containing anthrax spores mailed through the U.S. postal system killed five people and sickened 17, demonstrating how biological agents could be weaponized against civilians.
These events provided the political will for formal emergency mechanisms. Congress responded with the Project BioShield Act of 2004, which amended the FD&C Act to create the formal EUA authority. This gave the FDA explicit power to act swiftly against chemical, biological, radiological, and nuclear threats by authorizing medical countermeasures with less evidence than required for full approval.
The Philosophical Shift
The EUA framework represents a deliberate shift in the FDA’s core mission. It creates inherent tension between the agency’s historical role as cautious gatekeeper and its modern role as rapid responder in national security crises.
The foundational laws of the 20th century established a high, deliberative bar for product approval, prioritizing certainty and safety. The 2001 anthrax attacks created a new paradigm where speed was paramount. The EUA provision was the legislative response, creating a parallel regulatory track that intentionally lowers the evidence bar to meet the demand for speed.
The EUA isn’t merely an administrative shortcut but a legal embodiment of this philosophical conflict, forcing the agency to balance the risk of an unproven product against the risk of an unchecked public health threat.
How the EUA Process Works
Triggering an Emergency
The FDA cannot issue an EUA on its own initiative. The process must be triggered by a formal declaration that circumstances exist to justify emergency use of medical products.
Three cabinet-level officials can make this declaration: the Secretary of Health and Human Services, the Secretary of Defense, or the Secretary of Homeland Security.
A crucial legal distinction exists between an EUA-enabling declaration and a general Public Health Emergency declaration made under Section 319 of the Public Health Service Act. A Section 319 PHE declaration allows certain actions like making grants and entering contracts, but doesn’t by itself give the FDA authority to issue EUAs.
The COVID-19 pandemic illustrates this two-track system. The HHS Secretary first declared a nationwide PHE under Section 319 in January 2020. He then issued separate, specific determinations under Section 564 of the FD&C Act, which were necessary to authorize EUAs for different product categories: in vitro diagnostics (February 4, 2020), personal respiratory protective devices (March 2, 2020), and drugs and biological products (March 27, 2020).
The Four Legal Requirements
Once an emergency is declared, the FDA can consider an EUA request only if four specific legal conditions are met:
Serious or Life-Threatening Disease: The agent involved must be capable of causing a serious or life-threatening disease or condition.
Evidence of Potential Effectiveness: Based on available scientific evidence, it must be “reasonable to believe” that the product “may be effective” in diagnosing, treating, or preventing the disease. This is significantly lower than the “substantial evidence of effectiveness” required for full approval.
Favorable Risk-Benefit Analysis: The known and potential benefits of using the product in the emergency must outweigh its known and potential risks.
No Adequate Alternatives: There must not be any other suitable, FDA-approved products already available for the specific emergency situation.
The Five-Step Authorization Process
The EUA process generally follows five key steps:
Emergency Determination: A relevant cabinet Secretary determines that a public health emergency exists or has significant potential to exist.
Emergency Declaration: The Secretary formally declares that circumstances justify authorization of emergency use for medical products. A single declaration can serve as the basis for multiple EUAs for different products.
FDA Review: A manufacturer or government entity submits a request to the FDA. This can begin in a “pre-EUA” phase, where discussions and data submission start before an emergency is formally declared. The FDA may consult with other agencies like the National Institutes of Health and Centers for Disease Control and Prevention.
Authorization or Denial: If the FDA determines the four statutory criteria are met, the Commissioner issues the EUA. This includes a formal letter of authorization outlining conditions of use, plus mandatory fact sheets for healthcare providers and patients or caregivers. If criteria aren’t met, the request is denied.
EUA Termination: An EUA remains in effect for the duration of the underlying emergency declaration unless revoked sooner by the FDA. When the Secretary terminates the declaration, all related EUAs automatically cease.
Strategic Flexibility
The distinction between PHE declarations and EUA declarations provides significant strategic flexibility. Even after the general COVID-19 PHE declaration expired on May 11, 2023, the FDA stated this wouldn’t affect its ability to authorize treatments or keep existing EUAs in effect.
This is possible because the EUAs were based on a separate Section 564 determination of a public health emergency affecting national security, which remained active. This two-track system allows the government to wind down broad societal measures tied to a PHE while maintaining targeted, long-term public health and biodefense posture through the EUA mechanism.
EUA vs. Full FDA Approval
The difference between Emergency Use Authorization and full FDA approval isn’t merely about speed – it represents fundamental differences in scientific standards, legal status, and intended purpose.
Evidence Standards
EUA Standard: The law requires “reasonable belief” that the product “may be effective” based on the “totality of scientific evidence available.” This flexible standard can include promising but not yet definitive data, especially early in an evolving crisis.
Full Approval Standard: Full approval requires “substantial evidence” of effectiveness, typically met by conducting at least two adequate and well-controlled clinical trials designed to definitively prove the product works for its intended use.
Timeline and Manufacturing
These different evidence standards directly impact timeline and process.
Speed: The median time for a new vaccine to progress from Phase 1 clinical trial to full FDA approval is just over eight years. EUAs dramatically shorten this timeline. For COVID-19 vaccines, the FDA required safety data from a median of at least two months of follow-up after the final dose for an EUA, compared to at least six months for full approval.
Manufacturing: Under traditional approval pathways, companies typically invest in scaling up mass production after receiving full FDA approval to avoid financial risk. The EUA process allows – and in the case of COVID-19 vaccines, encouraged – manufacturers to produce millions of doses while clinical trials were ongoing. This “at-risk manufacturing” was a high-stakes financial gamble that enabled immediate distribution once EUAs were granted.
Legal Status
EUA Products: An EUA is temporary authorization, not full approval or license. Its validity is tied directly to the duration of the emergency declaration. Physicians generally cannot prescribe EUA products “off-label” for uses not specified in the authorization letter.
Approved Products: Full approval is permanent and allows indefinite commercial marketing. Once fully approved, physicians have discretion to prescribe products for off-label uses based on professional judgment and patient needs.
| Characteristic | Emergency Use Authorization | Full FDA Approval |
|---|---|---|
| Legal Standard for Efficacy | “Reasonable to believe the product may be effective” | “Substantial evidence of effectiveness” |
| Required Safety Data (COVID-19 Vaccines) | Median 2+ months of follow-up | 6+ months of follow-up |
| Review Timeline | Expedited; weeks to months | Standard; months to years |
| Manufacturing Scale-Up | Can occur during clinical trials | Typically occurs after approval |
| Duration | Temporary; lasts only during emergency | Permanent commercial marketing |
| Off-Label Use | Generally not permitted | Permitted based on physician judgment |
EUAs Through History
Anthrax: The First EUA
The 2001 anthrax attacks were the direct catalyst for creating EUA authority. The very first EUA for a vaccine was issued on January 27, 2005, for the Anthrax Vaccine Adsorbed, permitting its use for military personnel at high risk of exposure to inhalation anthrax.
The EUA was issued after a federal court injunction had halted the military’s mandatory anthrax vaccination program, making the authorization a critical legal tool to resume vaccinations for high-risk personnel. Over the years, other EUAs have been issued for anthrax countermeasures, including diagnostic tests and therapeutics like doxycycline for post-exposure treatment.
H1N1 Pandemic: First Civilian Use
The 2009 H1N1 influenza pandemic marked the first major deployment of EUAs for a widespread civilian public health crisis. The FDA issued EUAs for diagnostic tests to detect the new flu strain and for antiviral drugs like Tamiflu and Relenza, allowing their use in ways not covered by existing approvals.
A new antiviral drug, Rapivab, also received an EUA during the pandemic. That EUA expired in 2010 when the emergency declaration ended, and the drug later gained full FDA approval in 2014.
Ebola and Zika: Diagnostic Focus
During the Ebola outbreaks in West Africa, the FDA issued numerous EUAs primarily for novel diagnostic tests designed to quickly detect the virus in field settings where laboratory infrastructure was limited. A key authorization was for the first rapid fingerstick test that could be read by a portable, battery-operated device.
A notable pattern emerged: most diagnostic tests authorized for Ebola under EUA were never transitioned to full, permanent FDA approval.
Similarly, the Zika virus outbreak prompted a wave of EUAs for diagnostic tests due to the urgent need to identify infections linked to severe birth defects like microcephaly. With no commercially available FDA-cleared tests, the EUA mechanism was critical for providing access to tests that could detect the virus’s genetic material or the body’s antibody response.
COVID-19: Unprecedented Scale
The COVID-19 pandemic triggered the most extensive use of EUA authority in history, transforming it from a niche regulatory tool into a household term.
Diagnostics: The first COVID-19 EUA was issued on February 4, 2020, for a diagnostic test developed by the CDC. This was followed by hundreds of EUAs for molecular (PCR), antigen, and serology (antibody) tests from numerous manufacturers, enabling nationwide testing scale-up.
Therapeutics: The FDA granted EUAs for numerous treatments with varying success. These included the antiviral drug remdesivir, convalescent plasma, and monoclonal antibodies like bamlanivimab. Key oral antiviral therapeutics like Paxlovid and Lagevrio were authorized for high-risk patients to prevent progression to severe disease. Several products, including Paxlovid, remdesivir (Veklury), and Actemra, later gained full FDA approval for specific uses.
Vaccines: In a historic achievement, the FDA issued EUAs for brand-new vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson. This was unprecedented – prior to 2020, an EUA had never been granted for a novel vaccine intended for widespread use. These EUAs were based on data from large-scale, randomized clinical trials involving tens of thousands of participants. The Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) vaccines later received full FDA approval.
Benefits and Risks
The Lifeline Advantage
The primary benefit of EUA is speed. In public health emergencies, the mechanism allows potentially life-saving medical products to reach the public when waiting years for standard approval isn’t viable.
The COVID-19 pandemic provides the most powerful illustration. Without the EUA pathway, the first vaccines would have been delayed for many months, almost certainly resulting in countless preventable deaths and hospitalizations.
The Uncertainty Trade-off
The core risk of the EUA pathway stems from its greatest strength: the lower evidence standard. A product authorized because it “may be effective” can later prove ineffective or have an unfavorable risk-benefit profile once more robust data becomes available.
The EUA for the monoclonal antibody bamlanivimab was granted based on initial data that the study’s own authors noted required confirmation. The subsequent authorization of convalescent plasma was also based on uncertain data. These cases demonstrate how EUAs can lead to widespread use of interventions whose benefits aren’t clearly established, consuming scarce healthcare resources.
Another risk is that manufacturers may fail to conduct required follow-up studies after an EUA is granted. This can leave critical questions about long-term safety and true efficacy permanently unanswered, especially if the product isn’t commercially viable enough to warrant the expense of pursuing full approval.
Political Pressure and Public Trust
The EUA process, particularly during highly politicized crises, is vulnerable to external pressure that can threaten scientific integrity and damage FDA credibility.
The hydroxychloroquine case during COVID-19 provides the most prominent cautionary example. The drug received an EUA for treating hospitalized COVID-19 patients despite very limited and weak scientific data, seemingly in response to intense political advocacy from the White House and media figures.
Just months later, the FDA took the dramatic step of revoking the EUA after multiple rigorous clinical trials showed the drug was ineffective against COVID-19 and could pose significant risks, including serious cardiac adverse events.
This sequence – a scientifically questionable authorization under apparent political pressure, followed by public reversal – creates a narrative of regulatory error and political influence. This can erode public trust, the foundational currency of public health. A public that distrusts the FDA may be less likely to accept future recommendations, even those based on solid evidence.
Impact on Clinical Research
A major scientific community concern is that granting an EUA can inadvertently disrupt or derail the clinical trials needed to establish long-term safety and efficacy. Once a potentially life-saving product is available through EUA, it becomes ethically challenging to continue asking clinical trial participants to receive placebo.
If significant numbers of control group participants “cross over” to receive the newly authorized product, trials can lose statistical power. This makes it difficult or impossible to gather high-quality, long-term comparative data required for full FDA approval, leaving permanent gaps in scientific knowledge.
Life After Authorization
Safety Monitoring
Because EUAs are based on less data than full approvals, robust post-authorization safety monitoring is critical. Manufacturers are required to have active safety follow-up plans and must report adverse events to the FDA.
The FDA and CDC employ several surveillance systems to monitor EUA product safety as they’re used by millions of people:
Vaccine Adverse Event Reporting System (VAERS): Co-managed by CDC and FDA, VAERS is a national early warning system that collects and analyzes reports of adverse events after vaccination. Reports can be submitted by anyone, including healthcare providers, patients, and family members.
MedWatch: The FDA’s broader safety information and adverse event reporting program for drugs and medical devices, serving a similar early-warning function for non-vaccine products.
These passive surveillance systems are crucial for detecting rare side effects that may be too infrequent to appear in initial clinical trials.
Revising and Revoking EUAs
An EUA is dynamic authorization, not static. The FDA has authority to revise an EUA to change conditions – such as expanding eligible patient populations, adding new warnings, or modifying dosage – or to revoke it entirely.
The FDA can revoke an individual EUA if:
- The circumstances that originally justified the EUA no longer exist
- The criteria for issuance, such as favorable risk-benefit balance, are no longer met based on new scientific evidence
- Other circumstances make revocation appropriate to protect public health, including approval of better alternatives or manufacturer requests for revocation
End of Emergency Transitions
When the HHS Secretary terminates an entire EUA declaration, the action is announced in the Federal Register with advance public notice. This termination causes all related EUAs to cease being in effect.
Recognizing that sudden cessation of hundreds of authorizations would create massive disruption to hospital supply chains and patient care, the FDA has developed detailed transition plans. For medical devices authorized during COVID-19, this plan outlines a phased, 180-day transition period giving manufacturers clear timelines to either cease marketing or submit full marketing applications for permanent approval.
This structured “off-ramp” is designed to be pragmatic. If manufacturers submit marketing applications and the FDA accepts them for substantive review before the 180-day deadline, companies can often continue distributing devices while the FDA completes full review.
Even after an EUA is terminated or revoked, the law includes a provision allowing patients who began treatment while authorization was active to continue using the product, provided their physician deems it medically necessary.
The Regulatory Balancing Act
The EUA lifecycle reveals the FDA acting not just as scientific regulator but as pragmatic logistics and market manager. The structured processes for revision, revocation, and transition show a system designed to be flexible and adaptive, capable of both rapid deployment and orderly withdrawal of emergency countermeasures.
This demonstrates sophisticated regulatory approach that goes beyond simple “authorized/unauthorized” binary to actively manage market impact of emergency decisions, balancing the need to return to normal standards with the need to prevent supply shocks.
The Emergency Use Authorization authority represents one of the most significant regulatory innovations of the 21st century. Born from the trauma of 9/11 and the anthrax attacks, refined through various public health crises, and stress-tested during the COVID-19 pandemic, it has proven both its value and its vulnerabilities.
The mechanism fills a critical gap in the regulatory toolkit, providing a legal pathway to deploy medical countermeasures when traditional approval timelines would result in preventable deaths. At the same time, it forces difficult trade-offs between speed and certainty, between the risks of action and inaction.
The COVID-19 experience demonstrated both the power and the perils of emergency authorization. The rapid deployment of effective vaccines saved countless lives, while controversies over treatments like hydroxychloroquine highlighted the risks of political interference and premature authorization.
As public health threats continue to evolve – from emerging infectious diseases to bioterrorism to climate-related health challenges – the EUA authority will likely remain a cornerstone of America’s public health preparedness. The key will be learning from past experiences to ensure that this powerful tool serves its intended purpose: protecting public health while maintaining the scientific integrity that is the foundation of regulatory authority.
Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.